These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 11842389)
1. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389 [TBL] [Abstract][Full Text] [Related]
2. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P Semin Oncol; 2002 Feb; 29(1S2):48-55. PubMed ID: 28140092 [TBL] [Abstract][Full Text] [Related]
3. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999 [TBL] [Abstract][Full Text] [Related]
4. The role of mitoxantrone in the treatment of indolent lymphomas. Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217 [TBL] [Abstract][Full Text] [Related]
5. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224 [TBL] [Abstract][Full Text] [Related]
6. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Nastoupil LJ; McLaughlin P; Feng L; Neelapu SS; Samaniego F; Hagemeister FB; Ayala A; Romaguera JE; Goy AH; Neal E; Wang M; Fayad L; Fanale MA; Oki Y; Westin JR; Rodriguez MA; Cabanillas F; Fowler NH Br J Haematol; 2017 Apr; 177(2):263-270. PubMed ID: 28340281 [TBL] [Abstract][Full Text] [Related]
7. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572 [TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Hirt C; Schüler F; Kiefer T; Schwenke C; Haas A; Niederwieser D; Neser S; Assmann M; Srock S; Rohrberg R; Dachselt K; Leithäuser M; Rabkin CS; Herold M; Dölken G Br J Haematol; 2008 May; 141(5):631-40. PubMed ID: 18422779 [TBL] [Abstract][Full Text] [Related]
10. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734 [TBL] [Abstract][Full Text] [Related]
11. Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. Tsimberidou AM; Jiang Y; Ford RJ; Lichtiger B; Medeiros LJ; McLaughlin P; Cabanillas F; Sarris AH Leuk Lymphoma; 2002 Aug; 43(8):1589-98. PubMed ID: 12400601 [TBL] [Abstract][Full Text] [Related]
12. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339 [TBL] [Abstract][Full Text] [Related]
13. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Hiddemann W; Dreyling M; Unterhalt M Semin Oncol; 2003 Feb; 30(1 Suppl 2):16-20. PubMed ID: 12652460 [TBL] [Abstract][Full Text] [Related]
14. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044 [TBL] [Abstract][Full Text] [Related]
15. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539 [TBL] [Abstract][Full Text] [Related]
16. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Ma SY; Au WY; Chim CS; Lie AK; Lam CC; Tse E; Leung AY; Liang R; Kwong YL Br J Haematol; 2004 Mar; 124(6):754-61. PubMed ID: 15009063 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830 [TBL] [Abstract][Full Text] [Related]
18. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527 [TBL] [Abstract][Full Text] [Related]
20. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Czuczman MS Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]